{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:12:03Z","timestamp":1790140323763,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-11514-3","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T20:04:36Z","timestamp":1742414676000},"page":"5337-5347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-8369","authenticated-orcid":false,"given":"Sungmin","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Leithner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius E.","family":"Mayerhoefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent P.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofya","family":"Murina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Siskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir S.","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Zelefsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebert A.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"11514_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216","journal-title":"Lancet"},{"key":"11514_CR2","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR et al (2021) Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol 7:1635\u20131642","journal-title":"JAMA Oncol"},{"key":"11514_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP et al (2021) A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol 206:52\u201361","journal-title":"J Urol"},{"key":"11514_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","volume":"84","author":"DS Surasi","year":"2023","unstructured":"Surasi DS, Eiber M, Maurer T et al (2023) Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur Urol 84:361\u2013370","journal-title":"Eur Urol"},{"key":"11514_CR5","doi-asserted-by":"publisher","first-page":"e222148","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I et al (2023) Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer. Radiology 308:e222148","journal-title":"Radiology"},{"key":"11514_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40336-024-00631-6","volume":"12","author":"S Woo","year":"2024","unstructured":"Woo S, Freedman D, Becker AS et al (2024) Equivocal bone lesions on PSMA PET\/CT: systematic review and meta-analysis on their prevalence and malignancy rate. Clin Transl Imaging 12:485\u2013500","journal-title":"Clin Transl Imaging"},{"key":"11514_CR7","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D et al (2024) The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging 51:3753\u20133764","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11514_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bju.15152","volume":"126","author":"MY Chen","year":"2020","unstructured":"Chen MY, Franklin A, Yaxley J et al (2020) Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68 Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant? BJU Int 126:396\u2013401","journal-title":"BJU Int"},{"key":"11514_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2967\/jnumed.122.264334","volume":"64","author":"TE Phelps","year":"2023","unstructured":"Phelps TE, Harmon SA, Mena E et al (2023) Predicting outcomes of indeterminate bone lesions on 18F-DCFPyL PSMA PET\/CT scans in the setting of high-risk primary or recurrent prostate cancer. J Nucl Med 64:395\u2013401","journal-title":"J Nucl Med"},{"key":"11514_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","volume":"84","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP et al (2023) Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 84:491\u2013502","journal-title":"Eur Urol"},{"key":"11514_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP et al (2023) Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol 83:405\u2013412","journal-title":"Eur Urol"},{"key":"11514_CR12","first-page":"1644","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J et al (2022) The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med 63:1644\u20131650","journal-title":"J Nucl Med"},{"key":"11514_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M et al (2019) Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 5:856\u2013863","journal-title":"JAMA Oncol"},{"key":"11514_CR14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2967\/jnumed.124.267751","volume":"65","author":"M Bauckneht","year":"2024","unstructured":"Bauckneht M, D\u2019Amico F, Albano D et al (2024) Composite prediction score to interpret bone focal uptake in hormone-sensitive prostate cancer patients imaged with [18F]PSMA-1007 PET\/CT. J Nucl Med 65:1577\u20131583","journal-title":"J Nucl Med"},{"key":"11514_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2967\/jnumed.119.234898","volume":"61","author":"F Dietlein","year":"2020","unstructured":"Dietlein F, Kobe C, Hohberg M et al (2020) Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer. J Nucl Med 61:729\u2013734","journal-title":"J Nucl Med"},{"key":"11514_CR16","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","volume":"48","author":"EG Arnfield","year":"2021","unstructured":"Arnfield EG, Thomas PA, Roberts MJ et al (2021) Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. Eur J Nucl Med Mol Imaging 48:4495\u20134507","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11514_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-020-00618-0","volume":"10","author":"HD Zacho","year":"2020","unstructured":"Zacho HD, Ravn S, Afshar-Oromieh A et al (2020) Added value of 68 Ga-PSMA PET\/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous (99m)Tc bone scintigraphy. EJNMMI Res 10:31","journal-title":"EJNMMI Res"},{"key":"11514_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.943760","volume":"9","author":"M Orevi","year":"2022","unstructured":"Orevi M, Ben-Haim S, Abourbeh G et al (2022) False positive findings of [18F]PSMA-1007 PET\/CT in patients after radical prostatectomy with undetectable serum PSA levels. Front Surg 9:943760","journal-title":"Front Surg"},{"key":"11514_CR19","doi-asserted-by":"crossref","unstructured":"Stoffels M, Cousin F, Lamande M et al (2025) Characterization of exclusive rib lesions detected by [68Ga]Ga-PSMA-11 PET\/CT. Nucl Med Commun 46:95\u2013105","DOI":"10.1097\/MNM.0000000000001919"},{"key":"11514_CR20","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","volume":"48","author":"H Gr\u00fcnig","year":"2021","unstructured":"Gr\u00fcnig H, Maurer A, Thali Y et al (2021) Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging 48:4483\u20134494","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11514_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-020-00300-7","volume":"20","author":"F de Galiza Barbosa","year":"2020","unstructured":"de Galiza Barbosa F, Queiroz MA, Nunes RF et al (2020) Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging 20:23","journal-title":"Cancer Imaging"},{"key":"11514_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.crad.2024.05.013","volume":"79","author":"R Srinivasan","year":"2024","unstructured":"Srinivasan R, Cook GJR, Patel N, Subesinghe M (2024) Prostate specific membrane antigen (PSMA) avid nonprostatic benign and malignant disease: a pictorial review. Clin Radiol 79:639\u2013656","journal-title":"Clin Radiol"},{"key":"11514_CR23","doi-asserted-by":"publisher","unstructured":"Ridouani F, Alberto Vargas H, Holzwanger DJ et al (2024) Clinical, imaging, and technical factors associated with successful genomic profiling of bone biopsy tissue in prostate cancer. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.07.007","DOI":"10.1016\/j.euo.2024.07.007"},{"key":"11514_CR24","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M et al (2023) PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging 50:1466\u20131486","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11514_CR25","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA et al (2021) Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res 27:3674\u20133682","journal-title":"Clin Cancer Res"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11514-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11514-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11514-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:53:01Z","timestamp":1757145181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11514-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["11514"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11514-3","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Sungmin Woo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: Marius E. Mayerhoefer received honoraria for lectures from Siemens, GE, and BM but unrelated to the current work. Kent P. Friedman is a co-investigator on \u201cOptimizing timing of rhPSMA-7.3 (18F), for assessing site(s) of recurrent disease following radical prostatectomy\u201d (PI Herbert Lepor) but does not receive any salary support and is unrelated to the current work. David R. Wise has received consulting fees from Leap Therapeutics, Foundation Medicine, Pfizer, Janssen, Sanofi, Lilly, Labcorp, Myovant, Bayer, AstraZeneca, Accutar and has received travel funding from Pfizer and Bayer but unrelated to the current work. The other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required for this study because of the retrospective design and was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No overlap with prior studies.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}